Show simple item record

dc.contributor.authorAllott, L
dc.contributor.authorDa Pieve, C
dc.contributor.authorMeyers, J
dc.contributor.authorSpinks, T
dc.contributor.authorCiobota, DM
dc.contributor.authorKramer-Marek, G
dc.contributor.authorSmith, G
dc.date.accessioned2017-07-20T11:26:16Z
dc.date.issued2017-07-27
dc.identifier.citationChemical communications (Cambridge, England), 2017, 53 (61), pp. 8529 - 8532
dc.identifier.issn1359-7345
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/736
dc.identifier.eissn1364-548X
dc.identifier.doi10.1039/c7cc03572a
dc.description.abstractThe future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO). Herein, we report the evaluation of the octadentate molecule DFO-HOPO (3) as a suitable chelator for 89Zr and a more stable alternative to DFO. The molecule showed good potential for the future development of a DFO-HOPO-based bifunctional chelator (BFC) for the radiolabelling of biomolecules with 89Zr. This work broadens the selection of available chelators for 89Zr in search of improved successors to DFO for clinical 89Zr-immuno-PET.
dc.formatPrint
dc.format.extent8529 - 8532
dc.languageeng
dc.language.isoeng
dc.publisherROYAL SOC CHEMISTRY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleEvaluation of DFO-HOPO as an octadentate chelator for zirconium-89.
dc.typeJournal Article
dcterms.dateAccepted2017-07-07
rioxxterms.versionofrecord10.1039/c7cc03572a
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfChemical communications (Cambridge, England)
pubs.issue61
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.publication-statusPublished
pubs.volume53
pubs.embargo.termsNot known
icr.researchteamMedicinal Chemistry 1
icr.researchteamPET Radiochemistry
icr.researchteamPreclinical Molecular Imaging
dc.contributor.icrauthorDa Pieve, Chiara
dc.contributor.icrauthorKramer-Marek, Gabriela
dc.contributor.icrauthorSmith, Graham


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0